Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Scutellarin is a flavone that has been found in S. barbata and has diverse biological activities, including anticancer, lipid lowering, antioxidative, and neurocognitive properties.1,2,3 It inhibits proliferation of PC-9 and H1975 non-small cell lung cancer (NSCLC) cells in a concentration-dependent manner and induces apoptosis and autophagy when used at a concentration of 160 µM, effects that can be blocked by the autophagy inhibitor HCQ (Item No. 17911).1 Scutellarin (30 and 60 mg/kg per day) reduces tumor growth in an H1975 mouse xenograft model. It decreases serum total cholesterol and LDL-cholesterol and increases HDL-cholesterol in a high-fat diet-induced mouse model of non-alcoholic fatty liver disease (NAFLD) when administered at doses of 25 and 50 mg/kg.2 It decreases hepatic malondialdehyde (MDA), glutamic-oxalacetic transaminase (GOT), and glutamic-pyruvic transaminase (GPT) activity, increases catalase (CAT) and total antioxidative capacity (T-AOC) activity, and increases the hepatic expression of PPARγ, PGC-1α, and Nrf2 in the same model. Scutellarin (5, 25, and 50 mg/kg per day) also prevents deficits in spatial and novel object memory in rats in the Y maze and novel object recognition test, respectively.3
WARNING This product is not for human or veterinary use.
1. Scutellarin induces apoptosis and autophagy in NSCLC cells through ERK1/2 and AKT Signaling Pathways in vitro and in vivo. J. Cancer 9(18), 3247-3256 (2018).
2. Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-
3. Scutellarin alleviates lipopolysaccharide-